DKDavid J. H. F. Knapp

David J. H. F. Knapp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David J. H. F. Knapp has a total of 388 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genome-wide structural variant landscape following HDR-enhanced CRISPR editing in human hematopoietic stem and progenitor cells

    by Fanny-Meï Cloarec-Ung, Guy Sauvageau, Hilary M Sheppard, Peter M Lansdorp, David Jhf Knapp

    DNA-PK inhibitors (DNA-PKi) have emerged as potent enhancers of homology-directed repair (HDR) in genome editing, however, recent studies have reported that such inhibitors can induce large-scale structural variations (SVs) raising safety concerns. To investigate factors influencing SV induction in human hematopoietic stem and progenitor cells (HSPCs), we employed a combination of on-target long-read nanopore sequencing and unbiased genome wide detection of SVs using Strand-seq. Our results show that editing alone results in a high frequency of large on-target deletions which were modestly increased by DNA-PK inhibition and could be mitigated using DNA polǪ inhibitors. Genome-wide SVs were also induced at low frequencies by editing but were not substantially increased with DNA-PKi. SVs including translocations were, however, increased with multiple simultaneous editing. Our results highlight that edit-induced SVs are not limited to DNA-PKi enhanced protocols, thus careful assessment will be critical to ensure the safety of any edited therapeutic cell product.

  • Open Access

    Tumour-stroma signaling drives a reversible program with neural-like features in cancer-associated fibroblasts

    by Myriam Iliana Ibanez-Rios, Maëlle Batardière, Elham Dianati, Guillaume Serwe, Sajanth Kanagasingam, Alexandre Archambault-Marsan, Pierre Thibault, Marc Therrien, Vincent Ǫuoc-Huy Trinh, David J.H.F. Knapp

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, in part due to a dense and highly plastic tumor microenvironment dominated by cancer-associated fibroblasts (CAFs). In previous work, we identified a CAF population expressing a neural-associated NES+SOX4+NOTCH1+ program that increased with disease progression. The signals driving this state and the mechanisms regulating it remained unclear. Here, we investigated how tumor-derived signals activate this program and whether it represents a stable fibroblast identity or a reversible state. Using spatial transcriptomic data spanning normal pancreas to invasive carcinoma, we identified EGF, FGF2 and BDNF as candidate tumor-to-fibroblast signals associated with disease progression. Functional experiments in patient-derived CAFs and human fibroblast cell lines showed that EGF and FGF2 are sufficient to induce the NES+SOX4+NOTCH1+ program. Growth factor withdrawal reversed the NES+SOX4+NOTCH1+ program at both the protein and transcriptional levels, indicating that this state is dynamic and environment dependent. Single-cell transcriptomic analysis further revealed a multi-phase response involving early loss of fibroblast-associated features, transient activation of neural-associated genes, and a later stress-associated state. Regulatory analyses identified ETS-family transcription factors as key regulators of the program, while phosphoproteomic profiling and inhibitor studies showed that MAPK/ERK signaling plays a central role in its transcriptional activation. Finally, pan-cancer single-cell analysis showed that this state is enriched in CAFs and increases from normal to tumor tissue across multiple cancer types. Together, these findings define a reversible, growth factor-driven CAF program and identify signaling mechanisms that may provide opportunities to selectively modulate tumor-supportive fibroblast states.

  • Open Access

    Genome-wide structural variant landscape following HDR-enhanced CRISPR editing in human hematopoietic stem and progenitor cells

    by Fanny-Mei Cloarec-Ung, Guy Sauvageau, Hilary M Sheppard, Peter M. Lansdorp, David Jhf Knapp

    DNA-PK inhibitors (DNA-PKi) have emerged as potent enhancers of homology-directed repair (HDR) in genome editing, however, recent studies have reported that such inhibitors can induce large-scale structural variations (SVs) raising safety concerns. To investigate factors influencing SV induction in human hematopoietic stem and progenitor cells (HSPCs), we employed a combination of on-target long-read nanopore sequencing and unbiased genome wide detection of SVs using Strand-seq. Our results show that editing alone results in a high frequency of large on-target deletions which were modestly increased by DNA-PK inhibition and could be mitigated using DNA polQ inhibitors. Genome-wide SVs were also induced at low frequencies by editing but were not substantially increased with DNA-PKi. SVs including translocations were, however, increased with multiple simultaneous editing. Our results highlight that edit-induced SVs are not limited to DNA-PKi enhanced protocols, thus careful assessment will be critical to ensure the safety of any edited therapeutic cell product.

  • Open Access

    The Human Male Mammary Gland has Similar Epithelial Populations to Female but Distinct Composition and Transcriptional Properties

    by M-Iliana Ibañez-Rios, Syed Mohammed Musheer Aalam, Megan L. Ritting, Ashlyn Jore, Keyur Chaludiya, Chitra Priya Emperumal, James W. Jakub, Sarah A. McLaughlin, Amy C. Degnim, Judy C. Boughey, et al.

    The normal adult male breast has not been characterized at single-cell resolution, leaving the cellular basis of male breast cancer (MBC) biology undefined. Here we present an integrated single-cell RNA sequencing atlas of the adult human breast comprising 174,471 cells from 17 donors (3 male, 14 female), including 18,117 male-derived cells. This revealed that the male breast retains all three epithelial populations, basal (BC), luminal progenitor (LP), and luminal committed cells (LC), but with an increase in LC at the expense of BC and LP across all three male donors. Male LC were distinguished from female by elevated ESR1 and PGR mRNA, enrichment of RNA processing and ribosome biogenesis programs, reduced inflammatory cytokine and growth factor signaling, elevated estradiol gene set enrichment scores, and higher inferred activity of developmental patterning transcription factors. This pattern was observed across differential expression, gene ontology, ligand profiling, and regulon-based analyses, and was not restricted to sex chromosome-linked gene expression. This is consistent with the near-universal estrogen receptor (ER) positivity that characterizes MBC clinically. This atlas provides the first cellular and transcriptional reference for the normal male breast and a resource for investigating sex differences in mammary biology, germline susceptibility variant interpretation, and modeling breast malignancies.

  • Open Access

    A Rare Multipotent Peg-like Epithelial Cell is a Candidate Cell-of-Origin for High-Grade Serous Ovarian Cancer

    by Megan L. Ritting, Wenmei Yang, Syed Mohammed Musheer Aalam, Hui Zhao, Liang Feng, Jianning Song, Mihai G. Dumbrava, Wazim M. Ismail, Dong-Gi Mun, Chunling Hu, et al.

    To illuminate the origins of high-grade serous ovarian cancer (HGSOC), the most lethal and common form of ovarian cancer, we have created a comprehensive living organoid biobank of human fallopian tube tissue, which is thought to be the origin of this cancer. Through optimized culture protocols and integrated multi-omic profiling—including single-cell RNA sequencing, chromatin accessibility (ATAC) analysis, proteomics, and secretomics—we assembled the largest molecular atlas of the fallopian tube epithelium to date. This resource revealed diverse epithelial lineages and regulatory networks, including a rare, multipotent epithelial subpopulation with hybrid epithelial–mesenchymal features. Spatially localized to the basal epithelium and resembling mesonephric developmental precursors, these cells exhibit transcriptomic and proteomic similarities to the mesenchyme-like subtype of HGSOC, implicating them as potential cells-of-origin. Their molecular identity is preserved in organoid models, enabling future mechanistic and translational studies. This resource, which advances fundamental understanding of epithelial hierarchy and cancer susceptibility, provides a platform to inform early detection and prevention strategies for aggressive forms of ovarian cancer. Highlights: Establishment of a clinically annotated fallopian tube organoid biobank enables delineation of epithelial lineage hierarchies and differentiation capacity. Multi-omics integration defines robust, lineage-specific transcriptional and regulatory networks in the fallopian tube epithelium. A rare basal epithelial subpopulation with mesenchymal features aligns with a mesenchyme-like subtype of high-grade serous ovarian cancer. Rare basal ‘peg’ cells exhibit fetal mesonephric developmental transcriptional programs and are maintained ex-vivo in fallopian tube organoids.

  • Open Access

    Receptor Tyrosine Kinase Profiling Identifies Chronic Constitutive Floodgate Oxidative Signaling in Glutathione-Independent Human Mammary Luminal Progenitor Cells

    by Syed Musheer Mohammed Aalam, Megan L. Ritting, Hari Ps, Geng-Xian Shi, Kingsley Shih, Yifei Dong, Guruprasad Kalthur, Cao Miao, Yifan Yu, David Jhf Knapp, et al.

    The human mammary epithelium contains a subset of luminal progenitor (LP) cells that are distinct from basal cells in both lineage potential and redox biology. LPs are uniquely equipped to tolerate oxidative stress through glutathione-independent mechanisms and have been implicated as candidate cells of origin in basal-like breast cancers. In this study, we identify the receptor tyrosine kinase (RTK) cKIT (CD117), as a defining feature of LPs and a key mediator of their expansion. cKIT is developmentally restricted to the LP compartment via Polycomb-mediated epigenetic repression in basal and luminal-committed cells. It is expressed in scattered epithelial cells within both ductal and alveolar regions of resting human mammary glands. Using RTK-engineered MCF10A models, we demonstrate that cKIT ligand/stem cell factor (SCF)-activated wildtype cKIT signaling is sufficient to drive proliferation in the absence of epidermal growth factor (EGF) and that cKIT is responsive not only to canonical ligands but also to hydrogen peroxide (H₂O₂). In primary human LPs, cKIT is rapidly phosphorylated upon exposure to SCF and H₂O₂, with concomitant AKT activation. These responses are enhanced when cKIT and EGFR signaling are co-engaged, suggesting a cooperative mitogenic program. In mammary gland, phosphorylation of the antioxidant enzyme PRDX1 is selectively detected in LPs, consistent with a floodgate model of redox signaling in which transient oxidative inactivation of peroxiredoxins (PRDXs) facilitates RTK signaling under elevated intracellular reactive oxygen species conditions. Clinically, elevated cKIT expression is associated with shorter progression-free survival in certain basal-like breast cancer, supporting a link between LP-like redox signaling states and aggressive tumor behavior. Together, these findings define a redox-integrated RTK signaling axis centered on cKIT that drives LP expansion and is associated with poor outcomes in a subset of basal breast cancers. This work establishes a mechanistic framework for targeting redox-responsive progenitor populations in both regenerative and oncologic context.


  • Open Access

    Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

    by Fanny-Mei Cloarec-Ung, Jamie Beaulieu, Arunan Suthananthan, Bernhard Lehnertz, Guy Sauvageau, Hilary M Sheppard, David Jhf Knapp

    Precision gene editing in primary hematopoietic stem and progenitor cells (HSPCs) would facilitate both curative treatments for monogenic disorders as well as disease modelling. Precise efficiencies even with the CRISPR/Cas system, however, remain limited. Through an optimization of guide RNA delivery, donor design, and additives, we have now obtained mean precise editing efficiencies >90% on primary cord blood HSCPs with minimal toxicity and without observed off-target editing. The main protocol modifications needed to achieve such high efficiencies were the addition of the DNA-PK inhibitor AZD7648, and the inclusion of spacer-breaking silent mutations in the donor in addition to mutations disrupting the PAM sequence. Critically, editing was even across the progenitor hierarchy, did not substantially distort the hierarchy or affect lineage outputs in colony-forming cell assays or the frequency of high self-renewal potential long-term culture initiating cells. As modelling of many diseases requires heterozygosity, we also demonstrated that the overall editing and zygosity can be tuned by adding in defined mixtures of mutant and wild-type donors. With these optimizations, editing at near-perfect efficiency can now be accomplished directly in human HSPCs. This will open new avenues in both therapeutic strategies and disease modelling.


  • Open Access

    Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

    by Fanny-Meï Cloarec-Ung, Jamie Beaulieu, Arunan Suthananthan, Bernhard Lehnertz, Guy Sauvageau, Hilary M Sheppard, David Jhf Knapp

    Precision gene editing in primary hematopoietic stem and progenitor cells (HSPCs) would facilitate both curative treatments for monogenic disorders as well as disease modelling. Precise efficiencies even with the CRISPR/Cas system, however, remain limited. Through an optimization of guide RNA delivery, donor design, and additives, we have now obtained mean precise editing efficiencies >90% on primary cord blood HSCPs with minimal toxicity and without observed off-target editing. The main protocol modifications needed to achieve such high efficiencies were the addition of the DNA-PK inhibitor AZD7648, and the inclusion of spacer-breaking silent mutations in the donor in addition to mutations disrupting the PAM sequence. Critically, editing was even across the progenitor hierarchy, did not substantially distort the hierarchy or affect lineage outputs in colony-forming cell assays or the frequency of high self-renewal potential long-term culture initiating cells. As modelling of many diseases requires heterozygosity, we also demonstrated that the overall editing and zygosity can be tuned by adding in defined mixtures of mutant and wild-type donor. With these optimizations, editing at near-perfect efficiency can now be accomplished directly in human HSPCs. This will open new avenues in both therapeutic strategies and disease modelling.

  • A Human Cerebral Organoid Model of Neural Cell Transplantation

    by M. Iliana Ibanez-Rios, Melina Narlis, Colin A. Hammond, David J. H. F. Knapp

    The advancement of cell transplantation approaches requires model systems that allow an accurate assessment of transplanted cell functional potency. For the central nervous system, although xenotransplantation remains state-of-the-art, such models are technically challenging, limited in throughput, and expensive. Moreover, the environmental signals present do not perfectly cross-react with human cells. This paper presents an inexpensive, accessible, and high-throughput-compatible model for the transplantation and tracking of human neural cells into human cerebral organoids. These organoids can be easily generated from human induced pluripotent stem cells using commercial kits and contain the key cell types of the cerebrum. We first demonstrate this transplant protocol with the injection of EGFP-labeled human iPSC-derived neural progenitor cells (NPCs) into these organoids. We next discuss considerations for tracking the growth of these cells in the organoid by live-cell fluorescence microscopy and demonstrate the tracking of transplanted EGFP-labeled NPCs in an organoid over a 4 month period. Finally, we present a protocol for the sectioning, cyclic immunofluorescent staining, and imaging of the transplanted cells in their local context. The organoid transplantation model presented here allows the long-term (at least 4 months) tracking of transplanted human cells directly in a human microenvironment with an inexpensive and simple-to-perform protocol. It, thus, represents a useful model both for neural cell therapies (transplants) and, likely, for modeling central nervous system (CNS) tumors in a more microenvironmentally accurate manner.


  • Open Access

    Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

    by Fanny-Meï Cloarec-Ung, Jamie Beaulieu, Arunan Suthananthan, Bernhard Lehnertz, Guy Sauvageau, Hilary M Sheppard, David Jhf Knapp

    Precision gene editing in primary hematopoietic stem and progenitor cells (HSPCs) would facilitate both curative treatments for monogenic disorders as well as disease modelling. Precise efficiencies even with the CRISPR/Cas system, however, remain limited. Through an optimization of guide RNA delivery, donor design, and additives, we have now obtained mean precise editing efficiencies >90% on primary cord blood HSCPs with minimal toxicity and without observed off-target editing. The main protocol modifications needed to achieve such high efficiencies were the addition of the DNA-PK inhibitor AZD7648, and the inclusion of spacer-breaking silent mutations in the donor in addition to mutations disrupting the PAM sequence. Critically, editing was even across the progenitor hierarchy, did not substantially distort the hierarchy or affect lineage outputs in colony-forming cell assays or the frequency of high self-renewal potential long-term culture initiating cells. As modelling of many diseases requires heterozygosity, we also demonstrated that the overall editing and zygosity can be tuned by adding in defined mixtures of mutant and wild-type donor. With these optimizations, editing at near-perfect efficiency can now be accomplished directly in human HSPCs. This will open new avenues in both therapeutic strategies and disease modelling.